Back-to-back plenary presentations for LAURA and ADRIATIC Phase III trials reinforce the potential of Tagrisso and Imfinzi in early lung cancer settings
Acquisition will advance Merck’s integrated offering for viral vector manufacturing
Operationally ready by 2029, it will be the Company’s first-ever facility to cover the full manufacturing process for ADCs
To accelerate the development of next-generation radioconjugates to treat cancer
_256_384.jpg)
The overall transaction is expected to conclude over next 12-15 months subject to receipt of all relevant shareholder and regulatory approvals
Highlighting fully integrated organization, robust portfolio, and strategic priorities to drive long-term sustainable growth
IntoCell will provide proprietary drug-linker technologies using their Ortho-Hydroxy Protected Aryl Sulfate
If approved, patritumab deruxtecan would be a first-in-class HER3 directed DXd antibody drug conjugate for these patients
Boostimmune will have access to WuXi XDC's fully integrated one-stop bioconjugate platform
Good momentum in commercial CDMO business
Subscribe To Our Newsletter & Stay Updated
